Insulin Aspart-xjhz Becomes First Interchangeable Biosimilar Rapid-Acting Insulin

Biocon Biologics gains USFDA approval for Kirsty, Interchangeable Rapid-Acting Insulin Aspart - Express Pharma

Biocon Biologics, a fully integrated global biosimilars company and subsidiary of Biocon announced that the US Food and Drug Administration  (FDA) has approved Kirsty (Insulin Aspart-xjhz), 100 units/mL as an interchangeable*  biosimilar to NovoLog (Insulin Aspart). KIRSTY is a rapid-acting human insulin analogue indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. KIRSTY will be available as a single-pa…

Biocon Biologics Marks U.S. Milestone: First Interchangeable Biosimilar Approval - BioPatrika

FDA Approval of Biocon Biologics Kirsty™ – First Interchangeable Rapid-Acting Insulin Aspart In a breakthrough that reinforces India’s growing leadership in global biosimilars, Biocon Biologics has received U.S. FDA approval for Kirsty™ (Insulin Aspart-xjhz) — the first and only interchangeable rapid-acting insulin aspart biosimilar in the United States. This approval marks a significant leap forward […] The post Biocon Biologics Marks U.S. Mile…

Insulin Aspart-xjhz Becomes First Interchangeable Biosimilar Rapid-Acting Insulin

The agent, Kirsty, represents a more affordable alternative to Novolog.

FDA Approves Kirsty as First Interchangeable Insulin Aspart Biosimilar

The FDA has approved Kirsty, the first interchangeable insulin aspart biosimilar, enhancing access to affordable diabetes care for millions.